m3taversal
a756745c18
- What: Converted 132 broken wiki links to plain text across 41 health domain files. Added Vida to the Active Agents table in CLAUDE.md. - Why: Leo's PR #15 review required these two changes before merge. - Details: Broken links were references to claims that don't yet exist (demand signals). Brackets removed so they read as plain text rather than broken links. Co-Authored-By: Claude Opus 4.6 <noreply@anthropic.com>
4.5 KiB
| description | type | domain | created | source | confidence |
|---|---|---|---|---|---|
| Global healthcare venture financing reached 60.4 billion in 2025 but AI-native companies capture 54 percent of funding with a 19 percent deal premium while mega-deals over 100 million account for 42 percent of total and Agilon collapsed from 10 billion to 255 million | claim | health | 2026-02-17 | Health tech VC landscape analysis February 2026; OpenEvidence Abridge Hippocratic AI fundraising disclosures; Agilon Health SEC filings; Rock Health digital health funding reports 2025 | likely |
healthcare AI funding follows a winner-take-most pattern with category leaders absorbing capital at unprecedented velocity while 35 percent of deals are flat or down rounds
Global healthcare venture financing reached $60.4 billion in 2025, the strongest annual deployment in years, with digital health funding hitting $14.2 billion. But the headline number masks a deeply bifurcated market.
The winner-take-most dynamic: AI-native companies capture 54% of all sector funding with a 19% premium on average deal size. Category leaders are raising at unprecedented velocity -- OpenEvidence went from $1B to $12B valuation in under 12 months ($700M raised), Abridge raised $550M in four months reaching $5.3B, Hippocratic AI hit $3.5B with $404M total. These companies are absorbing the lion's share of capital. a16z, General Catalyst, and Kleiner Perkins each participated in 5+ mega-deals, functioning as kingmakers. Mega-deals ($100M+) accounted for 42% of total funding -- capital is concentrating in fewer, larger bets.
The losers: 35% of all 2025 deals were flat or down rounds -- the highest rate since 2022-2023. Agilon Health collapsed from ~$10B+ market cap at IPO to $255M, posting $110M quarterly net losses despite $5.89B in revenue. Calm went from $2B to $1B valuation despite 4x revenue growth. Cerebral cannot pay its fines. 600+ companies that last raised in 2021-2022 haven't raised again or exited, many facing valuation overhangs from peak-era multiples. Distressed exits are accelerating (Thirty Madison $1B to $500M, SteadyMD $25M exit after raising $40M).
The emerging consensus: healthcare AI is a platform shift, not a bubble, but the shift creates winner-take-most dynamics where category leaders absorb capital while everyone else fights for scraps. The IPO window is opening cautiously (Hinge Health at ~60% discount, Insilico Medicine in Hong Kong). 2026 demands fundamentals: clinical-grade evidence, regulatory clarity, proven path to profitability. 15 new unicorns were minted in 2025, predominantly in AI-enabled categories.
Relevant Notes:
- OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years -- the category-defining company in healthcare AI clinical workflows, $12B valuation
- ambient AI documentation reduces physician documentation burden by 73 percent but the relationship between automation and burnout is more complex than time savings alone -- Abridge at $5.3B represents the ambient documentation category winner
- AI diagnostic triage achieves 97 percent sensitivity across 14 conditions making AI-first screening viable for all imaging and pathology -- diagnostic AI companies like Viz.ai ($1.2B, stale 2022 valuation) face pressure to grow into peak-era valuations
- AI compresses drug discovery timelines by 30-40 percent but has not yet improved the 90 percent clinical failure rate that determines industry economics -- AI drug discovery (Insilico IPO, Recursion underperforming) shows the prove-it mode dynamic
- four competing payer-provider models are converging toward value-based care with vertical integration dominant today but aligned partnership potentially more durable -- Devoted Health at $16.1B and Alignment Healthcare at $4.1B represent VBC winners; Agilon at $255M represents the catastrophic failure mode
- Oura controls 80 percent of the smart ring market with patent-defended form factor while a demographic pivot from fitness enthusiasts to wellness-focused women drives 250 percent sales growth -- Oura's $900M raise at $11B exemplifies winner-take-most capital concentration in consumer health
- WHOOP subscription-only wearable model generates $260M revenue but trails Oura at half the revenue and a third the valuation because fitness-first positioning limits the addressable wellness market -- WHOOP's 4+ year fundraising gap illustrates the other side: companies that miss the capital wave face stale valuations
Topics:
- health and wellness